|
|
Enlarged prostate symptoms diagnosisDRE & Enlarged prostateIf bph symptoms occur, a physical examination- DRE (Digital Rectal Exam)- is performed followed by a neurologic examination. The size and consistency of the prostate gland are noted. BPH is usually felt like a smooth, firm, elastic enlargement of the prostate. If Induration is detected during the DRE, the physician should realize the possibility of cancer and request further evaluation (prostate-specific antigen test [PSA], transrectal ultrasound, biopsy). Symptoms assessmentThe self-administered questionnaire developed by the American Urological Association (AUA) is a perfect start when first symptoms of prostate enlargement are felt, as well as during the subsequent monitoring phases. It is a reliable source of information and is very important in identifying the need to treat patients and in monitoring their response to therapy. The AUA Symptom Score questionnaire (see following table) is perhaps the single most important tool used in the evaluation of patients with BPH symptoms and is recommended for all patients before the initiation of therapy. This assessment focuses on 7 items that ask patients to quantify the severity of their obstructive or irritative symptoms on a scale of 0-5. Thus the score can range from 0 to 35. According to McConnell et al, 1994, the relative distribution of scores for patients with BPH symptoms and for control subjects is:
This is what the questionnaire looks like: International Prostate Symptom Score (I-PSS)
Laboratory tests to assess prostate enlargement/BPHPsa score for bphProstate specific antigen (PSA) is a protease secreted by epithelial cells of the prostate. It was found to be elevated in 30% to 50% of patients with an enlarged prostate. Testing for PSA is used mostly to increases detection rate for prostate cancer and tends to detect cancer at an earlier stage. However, the PSA test does not discriminate well between patients with symptomatic BPH/enlarged prostate and those with prostate cancer, especially if the cancers are pathologically localized and curable. The test may also provide additional guidance concerning additional evaluation options, including ultrasound biopsy of the prostate. Recent data show that asymptomatic men with PSA levels <2 ng/ml do not need annual testing. According to the AUA policy report published in the February 2000 issue of Oncology, PSA testing and digital rectal examination should be offered to any asymptomatic man older than 50 years of age with a life expectancy of =10 years.PSA testing can also be done at an earlier age in those men with a higher risk of prostatic cancer (e.g., black men, or first-degree relatives with prostate cancer). Measurement of "free" PSA is useful to assess the probability of prostate cancer in patients with normal digital rectal examination and total PSA between 4 and 10 ng/ml. In these patients the global risk of prostate cancer is 25%; however, if the free PSA is >25%, the risk of prostate cancer decreases to 8%, whereas if the free PSA is >10%, the risk of cancer increases to 56%. Free PSA is also useful to evaluate the aggressiveness of prostate cancer. A low free PSA percentage generally indicates a high-grade cancer, whereas a high free PSA percentage is generally associated with a slower growing tumor. In order to exclude exclude infection or hematuria (if any is suspected) a urinalysis test should be performed. BUN (Blood Urea Nitrogen) and creatinine should be performed to rule out postrenal insufficiency. A BUN test is done to estimate the function of yor kidneys. BUN level increases when the kidneys are not able to remove urea from the blood. Imaging studies for BPH symptoms
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
